By Callum Keown
European markets were dragged down on Thursday as trade talks between the U.S. and China ground to a halt over Huawei.
The DAX /zigman2/quotes/210597999/delayed DX:DAX -1.65% was the worst performing index, falling 0.8% after Germany’s most valuable company SAP /zigman2/quotes/203458330/delayed DE:SAP +0.66% dropped 6% as the trade war hit earnings.
What’s moving the markets?
Trade talks between the U.S. and China have stalled as the Trump administration weighs up what to do about Huawei, The Wall Street Journal reported.
Beijing has demanded the U.S. ease restrictions on the Chinese telecommunications giant but U.S. officials are undecided.
Wall Street lost further ground on Wednesday after Netflix /zigman2/quotes/202353025/composite NFLX +1.52% reported a drop in subscribers and IBM /zigman2/quotes/203856914/composite IBM +0.30% also posted a revenue slide.
The negative sentiment spilled over into Europe on Thursday sending stocks spiralling down.
Speaking to MarketWatch, Connor Campbell, Spreadex analyst said: “The European markets were on a short leash led by the U.S. on Thursday.
“Reports that the US-China trade talks have hit a Huawei-wall cast a red cloud over the likes of the DAX and FTSE, the fear being that it wouldn’t take much for the fragile truce between the superpowers to unravel — especially with Donald Trump once again talking up tariffs on Chinese goods.”
Which stocks are active?
German software giant SAP /zigman2/quotes/203458330/delayed DE:SAP +0.66% blamed global trade tensions as its second quarter profits missed expectations, sending shares down 5.7%
EasyJet /zigman2/quotes/202825892/delayed UK:EZJ -8.11% shares climbed 3.1% after the low-cost airline reported an 11% sales jump to £1.76bn in the third quarter, led by a spike in late bookings for the summer and a strong Easter performance.
Swiss pharma company Novartis /zigman2/quotes/203286410/delayed CH:NOVN -0.42% rose 5% after raising its full-year sales and income guidance following strong second quarter sales. The drug giant cited innovative medicine sales and rising international demand for its Sandoz generic and biosimilar unit.